(2026). Estimated Cost of Adverse Event Management in Treatment Naïve Non-small Cell Lung Cancer Patients with Common EGFR Mutations Treated with Amivantamab Plus Lazertinib and Osimertinib Plus Chemotherapy. Journal of Health Economics and Outcomes Research.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Estimated Cost of Adverse Event Management in Treatment Naïve Non-small Cell Lung Cancer Patients with Common EGFR Mutations Treated with Amivantamab Plus Lazertinib and Osimertinib Plus Chemotherapy."
Journal of Health Economics and Outcomes Research 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Estimated Cost of Adverse Event Management in Treatment Naïve Non-small Cell Lung Cancer Patients with Common EGFR Mutations Treated with Amivantamab Plus Lazertinib and Osimertinib Plus Chemotherapy."
Journal of Health Economics and Outcomes Research, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.